Axitinib decreases the disruption of tight junction proteins and reduces permeability of the BBB in AD disease mice while also increasing spatial awareness, exploration, associative memory, working memory and lowered amyloid-beta, indicating the potential for this drug to slow disease pathology [136]
As the market grows, patients and providers will need trustworthy resources to navigate these options
These medicines include semaglutide (marketed as Ozempic for diabetes and Wegovy for weight management), liraglutide (Victoza for diabetes and Saxenda for weight management), dulaglutide (Trulicity, for diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for weight management), which combines GLP-1 action with glucose-dependent insulinotropic polypeptide (GIP) receptor agonism
GLP-1 Medication Pricing (First 3 Months): $385/month with card $360/month with cash No membership fees
To be used: Face